British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American rival of ...

GSK PLC GSK shares inched up 0.03% to £14.97 Thursday, on what proved to be an all-around favorable trading session for the ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of p1,500.00. The company’s shares ...

FDA accepted GSK's gepotidacin application for uUTI treatment with a PDUFA date set for March 26, 2025. Gepotidacin showed superior efficacy over nitrofurantoin in EAGLE-3 trial with a 58.5% ...

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center (BMC) have announced a new collaboration with the global biopharma company GSK to ...

GSK rises after settlement of 80,000 Zantac litigations Precious metal miners jump on gold surge FTSE 100 down 0.1%, FTSE 250 off 0.6% Oct 10 (Reuters) - The UK's main stock indexes slipped on ...

CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines. The grant comes from the ...

GSK Plc CEO Emma Walmsley doesn’t want the company’s employees spending any time thinking about the ongoing litigation over its old heartburn drug Zantac, an issue that has weighed on the ...

GSK Plc, Sanofi, and CSL Ltd. secured $72 million from the US government to ramp up production of bird flu vaccines as a nationwide outbreak among livestock and poultry has led to several human ...

GSK recently announced the discontinuation of its herpes simplex virus (HSV) therapeutic vaccine candidate, GSK3943104, following the failure of a Phase I/II clinical trial to meet its primary ...

With this pipeline, GSK plc (NYSE:GSK) aims to generate £38 billion in sales in 2031. If achieved, this would enable the firm to grow its current trailing twelve month revenue of £31 billion by 21%.